From Yahoo Finance: 2025-06-02 17:08:00

Merck is in talks to acquire Swiss biotech MoonLake Immunotherapeutics for over $3 billion, according to the Financial Times. MoonLake’s stock surged 19% in after-hours trading. Merck’s initial offer was rejected, but discussions may resume. The move comes before MoonLake’s drug clinical data release, increasing its appeal for acquisition. Other bidders could still emerge. Merck has not commented on the potential deal. Keytruda’s patent expiration in 2028 and declining Gardasil revenue in China have prompted Merck to seek growth opportunities through acquisitions.



Read more at Yahoo Finance: Merck held talks to buy biotech MoonLake for over $3 billion, FT reports